Effect of Dietary Supplementation on Dynamic Stability

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-30

Study Completion Date

2017-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether specific nutrient supplementation can improve dynamic stability in older adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Oxidative Stress Links Aging, Activity, and Mobility Limitation

NCT01177189

Aging

TERMINATED NA

Effects Of Daily Taurine Intake For 6 Months On Biological Age and Body Metabolism Indicators As Well As Physical Fitness In 55-75-year-old Women And Men

NCT06613542

Taurine Aging, Biological Physical Activity +6 more

COMPLETED NA

Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults

NCT02921659

Aging

COMPLETED PHASE1/PHASE2

Supplement Study: Strength, Testosterone, Sexual Function, Quality of Life

NCT03457740

Muscular Weakness Sexual Behavior Quality of Life

COMPLETED NA

Vitamin and Mineral Supplementation Improves Micronutrient Status in Older Adults

NCT03061409

Nutrient Deficiency

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objective of this study is to evaluate the effect of a single nutrient dietary supplement on dynamic stability in an older population. Dynamic stability, or walking stability, will be assessed with accelerometers while subjects are walking on a flat surface for about 60 seconds. Dynamic stability will be defined by the maximum Lyapunov exponent (maxLE), Floquet multiplier, or motor control timing, change from baseline. Postural stability will also be measured in a still and standing subject, with foot placement standardized on a force plate, and with the subject looking in the forward direction with arms by their sides. Two visual conditions will be given: eyes-open (EO) and eyes-closed (EC). Each measurement will last for 60 seconds and will be repeated twice for each condition. A three-minute rest will be provided between measurements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dietary Supplement

This experimental arm reflects administration of a softgel capsule containing a dose of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol below the upper tolerable limit

Group Type EXPERIMENTAL

(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol

Intervention Type DIETARY_SUPPLEMENT

25 micrograms of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol every day for 6 months

Control

This experimental arm reflects administration of placebo in softgel capsule

Group Type EXPERIMENTAL

Control

Intervention Type OTHER

Placebo in Softgel form

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol

25 micrograms of (1S,3Z)-3-\[(2E)-2-\[(1R,3aS,7aR)-7a-methyl-1-\[(2R)-6-methylheptan-2-yl\]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene\]ethylidene\]-4-methylidenecyclohexan-1-ol every day for 6 months

Intervention Type DIETARY_SUPPLEMENT

Control

Placebo in Softgel form

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subject has voluntarily signed and dated an informed consent form (ICF), approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), and provided Health Insurance Portability and Accountability Act (HIPAA) (or other applicable privacy regulation) authorization prior to any participation in the study.
2. Subject is male or female and is ≥ 65 and ≤ 85 years of age.
3. Subject has Body Mass Index (BMI) ≥ 20 but ≤ 32 kg/m2.
4. Subject is ambulatory and able to walk ≥ 25 meters without the use of an assistive device.
5. Subject has a serum 25-hydroxyvitamin D level ≥ 7.5 but ≤ 22.5 ng/ml (18.75 to 56.25 nmol/L) at screening.
6. Subject agrees to apply sunscreen (≥ SPF 30) on any exposed skin, when expecting an increase in exposure to sunlight (e.g. a planned holiday of more than eight days, a beach holiday or a holiday in the southern hemisphere, for the duration of the study).
7. Subject agrees not to use tanning beds for the duration of the study.
8. Subject agrees to refrain from starting any new exercise program, or weight loss program, for the duration of the study.
9. Subject is able to follow the protocol.

Exclusion Criteria

1. Subject states they regularly consume supplemental vitamin D in the amount greater than the age-specific Institute Of Medicine daily recommended dietary allowance (600 IU or 15 µg for a subject ≥ 65 to ≤ 70 years of age; 800 IU or 20 µg for a subject \> 70 years of age). Supplemental vitamin D includes standalone vitamin D supplements, vitamin D supplements with calcium, multi-vitamins, any medications containing vitamin D, and purposefully seeking sunlight when outdoors.
2. Subject states they have received vitamin D3 by injection within the last 3 months.
3. Subject is missing, or has had an amputation of, a limb.
4. For a subject who reports \> 2 falls within the last year, or one fall within the last year with injury, study physician and study PI must approve participation in the study.
5. Subject states they have an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g. dysphagia) and digestion (e.g., known intestinal malabsorption, celiac disease, inflammatory bowel disease, chronic pancreatitis, steatorrhea).
6. Subject states they have sarcoidosis, lymphoma, primary hyperparathyroidism, or any other disease that may enhance serum calcium concentration, as determined by the study physician.
7. Subject states they have had kidney stones within the last 3 years.
8. Subject states they have abnormal indices of calcium metabolism including hypercalcemia.
9. Subject states they have a granulomatous disease such as sarcoidosis, active chronic tuberculosis, and Wegener's granulomatosis.
10. Subject states they have been diagnosed with renal failure, renal insufficiency, or chronic kidney disease, or has received hemodialysis.
11. Subject states they have an active malignant disease, except basal or squamous cell skin carcinoma or carcinoma in situ of the uterine cervix.
12. Subject states they have liver failure (decompensated chronic liver disease).
13. Subject has a stated history of a significant cardiovascular event (e.g., myocardial infarction, heart failure, or stroke) ≤ 3 months prior to screening visit.
14. Subject states they are currently diagnosed with, or has a history of severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study dietary supplement consumption or compliance with study protocol procedures in the opinion of the principal investigator or study physician.
15. Subject reports having undergone major surgery, less than 6 weeks prior to enrollment in the study, or subject has planned inpatient surgery requiring 2 or more days of hospitalization during the entire study.
16. Subject states they have undergone hip replacement surgery within the last year.
17. Subject states they are currently being prescribed (by primary care physician or other health professional) medication that in the opinion of the study physician will have an effect on serum 25-hydroxyvitamin D levels (e.g., certain anticonvulsants, phenobarbital, carbamazepine, phenytoin).
18. Subject states they have been undergoing treatment within the last 2 years for epilepsy, and the treatment has an effect on serum 25-hydroxyvitamin D.
19. Subject states they have been prescribed within the last 2 years bisphosphonates or parathyroid hormone.
20. Subject states they cannot refrain from anabolic hormones or growth hormone, starting at screening and over the entire course of the study.
21. Subject reports alcohol intake as average of 3 or more servings per day (a serving defined as 4 oz wine, 12 oz beer, 1 oz spirits).
22. Subject states they have an allergy or intolerance to any ingredient in the study product.
23. Subject is deemed unsuitable for study based upon study physician assessment.
24. Subject is taking part in another clinical trial.
25. The use of fat absorption inhibiting products (e.g., prescription orlistat (Xenical), over the counter orlistat (Alli)) during the study.

Minimum Eligible Age

65 Years

Maximum Eligible Age

95 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes